Nov. 14 at 11:39 PM
$CRMD $CDTX
After coming across CRMD, I researched the AWG earlier in the year, came across Cidara Therapeutics, recent 10xer &
$MRK acqusisition.
There were about 15-20 companies in the AWG (incl. CRMD & Melinta pre-acquisition, and Cidara).
I believe the remaining milestone payments & future royalties on REZZAYO will find their way to Cidara - & Melinta did not add any costs here.
AI tells me the original licensing agreement between Melinta and Cidara could be up to
$410M (in regulatory and commerical milestone) in value, with a small portion of this paid up. I'm not sure if this figure includes an estimate of future royalties.
https://www.pharmaceutical-technology.com/news/cidara-receives-20m-payout-after-fda-backs-for-rezzayo/?cf-view&cf-closed
"The
$20M received by Cidara is part of an initially agreed
$60M in regulatory milestone payments. Cidara is also in line to scoop
$370M in commercial payments, to add to the
$30M received upfront when the deal was signed. It puts the total potential transaction value at
$460M."
CRMD claim only
$25M milestone outstanding plus royalties.
